The Effects of Statin and Fibrate on Lowering Small Dense LDL- Cholesterol in Hyperlipidemic Patients with Type 2 Diabetes-Reference-Cited by-同舟云学术

The Effects of Statin and Fibrate on Lowering Small Dense LDL- Cholesterol in Hyperlipidemic Patients with Type 2 Diabetes

Published:2007 Issue:3 Volume:14 Page:128-132
ISSN:1880-3873
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Tokuno Anna,Hirano Tsutomu,Hayashi Toshiyuki,Mori Yusaku,Yamamoto Takeshi,Nagashima Masaharu,Shiraishi Yuji,Ito Yasuki,Adachi Mitsuru

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry, medical,Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/14/3/14_3_128/_pdf

Reference18 articles.

1. Metabolic origins and clinical significance of LDL heterogeneity

2. 2) Lamarche B, Lemieux I, and Després JP: The small dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metabolism, 1999; 25: 199-211

3. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women

4. Remarkably high prevalence of small dense low-density lipoprotein in Japanese men with coronary artery disease, irrespective of the presence of diabetes

5. Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart disease

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fibrate and the risk of cardiovascular disease among moderate chronic kidney disease patients with primary hypertriglyceridemia;Frontiers in Endocrinology;2024-02-13

2. Can Concurrent Fibrate Use Reduce Cardiovascular Risks among Moderate Chronic Kidney Disease Patients Undergoing Statin Therapy? A Cohort Study;Journal of Clinical Medicine;2023-12-28

3. Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis;Clinical Gastroenterology and Hepatology;2023-09

4. Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy;Journal of Diabetes Investigation;2023-08-30

5. Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis;Metabolites;2023-05-02